Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 1, 2019

Primary Completion Date

March 1, 2024

Study Completion Date

July 1, 2024

Conditions

Cervical Cancer

Interventions

DRUG

Avelumab

an anti-programmed cell death ligand 1

DRUG

Axitinib

a tyrosine kinase inhibitor that also inhibits VEGF receptor 1-3, c-KIT and PDGFR

Trial Locations (1)

The University of Hong Kong, Hong Kong

All Listed Sponsors

lead

The University of Hong Kong

OTHER

NCT03826589 - Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based Chemotherapy | Biotech Hunter | Biotech Hunter